Pfizer Initiates Phase III Trial For PCSK9; Raises Doubts About Regulatory Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma discussed the late-stage program for its cholesterol-lowering drug during a third quarter conference call, noting it will be prepared with CV outcomes data should FDA require it for approval of the PCSK9 inhibitor.